Amniox designates gift during Wound Healing Society’s 2021 Fall Symposium on Advanced Wound Care to support clinicians in treating severe chronic wounds that can result from diabetic foot ulcers

Miami, FL – December 1, 2021 – Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue products, announced today that it has gifted the American Diabetes Association (ADA) with a $10,000 donation to support scientific research and prediabetes education. Amniox has been a longtime proponent for the advancement of clinical research of this type. In November 2020, the organization launched their first of two multi center randomized controlled Phase 3 Clinical Trials studying human birth tissue-based products to treat complex Wagner Grade 3 and 4 diabetic foot ulcers. These studies are currently being conducted at 20 investigational sites across the United States.

This gift demonstrates Amniox’s long-standing commitment to the furtherance of scientific research. The organization is in solid alignment with the ADA’s longstanding commitment to supporting the next generation of diabetes researchers.

“We are proud to support the ADA and applaud the research and educational efforts of the ADA and Wound Healing Society,” said TissueTech President and Chief Executive Officer Amy Tseng. “For over a decade, Amniox has been recognized as a leader in complex wound management through our clinical research and medical contributions. Currently, we are conducting two clinical trials studying an investigational new drug to achieve complete wound closure of complex non-healing diabetic foot ulcers with high-risk factors of ulcer depth indicating exposed bone, tendon, muscle, and/or joint capsule, and clinical suspicion of osteomyelitis.”

Results from an earlier one-year follow-up study published in the peer-reviewed journal Wound Repair and Regeneration indicate that TTAX01 is a promising adjunct therapy with a higher healing rate than Standard of Care (SOC) for the management of advanced diabetic foot ulcers complicated by osteomyelitis.1 The Amniox leadership team hopes to parley these research results to ultimately reduce healthcare costs when treating complex wounds. In one study published by the Alliance of Wound Care Stakeholders, researchers found that chronic non-healing wounds impact nearly 15% of Medicare beneficiaries (8.2 million) with an estimated annual cost is $28 billion2.

About TissueTech, Inc.

TissueTech, Inc. is an emerging biotechnology company and leader in regenerative medicine using human birth tissue. TissueTech’s pioneering amniotic membrane products are processed using its proprietary CRYOTEK® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. Today, TissueTech is breaking new ground with multiple Investigational New Drug clinical trials underway as the company pursues 351 biologics’ approval for products to treat patients’ unmet clinical needs. TissueTech is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 600,000 human implants with its products and published over 380 peer-reviewed studies supporting TissueTech’s platform technology. Learn more at https://tissuetech.com.

About Amniox Medical, Inc.

Amniox Medical, Inc. is a TissueTech, Inc. company. It is focused on harnessing the unique power of human birth tissue to support regenerative healing and functional recovery in surgical, chronic wound, and musculoskeletal applications. The Amniox family of cryopreserved amniotic membrane products are processed using its proprietary CRYOTEK® cryopreservation technology to retain the birth tissue’s structural and functional integrity. Amniox is committed to facilitating optimal clinical outcomes, solving previously unmet clinical and patient needs, and positively impacting patients’ lives. Connect with Amniox on our Website, Physician Portal, Facebook, LinkedIn, Instagram, and Twitter, or through your local sales professional.


1. Marston, WA, Lantis, JC, Wu, SC, et al. One‐year safety, healing and amputation rates of Wagner 3‐4 diabetic foot ulcers treated with cryopreserved umbilical cord (TTAX01). Wound Rep Reg. 2020; 1– 6. https://doi.org/10.1111/wrr.12809 Marston, W. A., Lantis, J. C., Wu, S. C., Nouvong, A., Lee, T.
2. http://www.woundcarestakeholders.org/images/documents/2017/Fact_Sheet-Economic_Burden_of_Wounds_10.5.17.pdf